All posts by Business Review Webinars

Spotlight Interview with Renan Joel, Event Director of Easyfairs’ UK Packaging Portfolio, discusses what he is most looking forward to when Packaging Innovations 2020 returns to the NEC on 26 & 27 February.

What do you hope attendees will gain from your event?

Packaging Innovations NEC is the largest packaging event in the UK and is unique in its offering. Incorporating our co-located events Ecopack, Contract Pack & Fulfilment, Label&Print, and Empack, it is the only exhibition which caters for the whole of the packaging supply chain, all under one roof, and allows visitors the opportunity to meet with over 300 industry leading suppliers.

By providing this unique platform, the show offers industry professionals the opportunity to discover the most cutting-edge tools and solutions for every aspect of their packaging process, from concept through to fulfilment.

What discussions do you look forward to having with the attendees?

Sustainability is a hot topic across the industry right now and I’m looking forward to discussing this with our visitors. It is a complex, multi-faceted issue and there certainly isn’t a one size fits all approach to creating truly eco-friendly packaging. It is a topic that will be taking centre stage throughout our seminar programme and will form the basis of our new BIG Carbon Debate, which aims to tackle the challenge of creating packaging that is truly sustainable throughout its entire lifecycle. Sustainability will also be a key focus across the show floor, with many exhibitors set to launch their sustainable solutions live at the event.

What do you enjoy most about your role? 

It’s innovative and requires original ideas. As lifestyles change, materials evolve and the competition for branding and market share continues. Packaging is the billboard for a product and its brand strategy. I just love the idea of joining such an amazing industry.

How did you get into the industry?

I have been in the events industry for over five years. Following university, where I studied business administration, I achieved my master’s degree in Marketing and Sales. I was approached by a head-hunter to join the event industry. I fell in love with its dynamism and the possibility of working in a different industry and meeting interesting people. This will be my first Packaging Innovations and I’m excited to begin this new journey on such a well-known and respected event.

Where is your favourite place in the world and why?

The UK, for sure. This is a country of opportunities with an amazing culture and history.

For further information, please visit the Packaging Innovations NEC 2020 website or contact the show team on +44 (0)20 8843 8800 or

The Complex Issue of Sustainability in Packaging

Author: Renan Joel, Event Director of Packaging Innovations NEC 2020

Sustainability is one of the hottest topics within the packaging industry right now. For several years there has been a heavy focus on plastic as both the industry and consumers asked themselves how the reliance on single-use plastic products could be reduced and if there are sustainable alternatives out there that we should be using. However, the issue of sustainability cannot simply be solved by eliminating plastic in favour of alternative materials. It is much more complex than that.

Plastic is so often incorporated in packaging because it performs a vital role – to protect the product. For industries where there are strict regulations in place, such as throughout the food and pharmaceutical sectors, plastic often remains the option that is the best fit for purpose.

Where plastic can be substituted though, it is essential that we consider the entire lifecycle of packaging, and how materials perform at each stage, in order to find truly sustainable solutions. From raw material to disposal, every step of the supply chain has its own impact on the environment.

It’s undeniable that we have a single-use plastic problem. Indeed, in the UK alone it is estimated that five million tonnes of plastic is used every year, nearly half of which is packaging and only a quarter of which is recycled. However, simply replacing plastic with a ‘greener’ material doesn’t necessarily solve the problem. The resources needed to manufacture, transport, and dispose of alternatives can, in some instances, result in more damage to the environment than the plastic we are trying to replace.

We only need to look at the topics that have been hitting the headlines in recent months to get a sense of the complexity of the problem. For instance, the water and time needed to grow wood for paper used in packaging and the carbon impact of sourcing and shipping materials from overseas have all been put under the spotlight in recent weeks as consumers increasingly consider sustainability at every point in a product’s lifecycle. With this in mind, it’s also important that we weigh up the credentials of recyclable solutions against packaging that can be used hundreds of times, reducing the need to create new packaging from raw materials.

This shift in focus will take centre stage at Packaging Innovations 2020, where leading industry experts will discuss the complex issue of creating packaging that is sustainable at every point in its lifecycle during our new seminar platform, the BIG Carbon Debate. The demand for packaging isn’t decreasing, after all, many of the products we buy will always need to be packaged in some way. However, we do have control over how we create and dispose of it and we strongly believe that the key to finding the sustainable answer is collaboration.

For further information, please visit the Packaging Innovations NEC 2020 website or contact the show team on +44 (0)20 8843 8800 or


On January 21 2020, we will be hosting a webinar on the use of 3D bioprinting to generate in-vitro skin models. You are invited to join us! Register for free here.

During the webinar we will hear about the potential of printing cell-laden biomaterials to create functional skin in the lab. We will learn from experts at Regemat3D who are working on developing a reproducible 3D printed layered skin model. As part of Biogelx’s ongoing collaboration with Regemat3D, researchers from the bioprinting company are using Biogelx-INKs for the generation of such advanced models.

Today, we are thrilled to introduce Dr. Jose Manuel Baena and Mario Juarez-Rodriguez as our invited webinar speakers. Jose Manuel is the CEO and founder of REGEMAT 3D, a leading bioprinting company based in Granada, Spain. Mario is a bioprinting scientist at the Platform for Tissue Engineering and 3D Printing (PITI3D), Regemat3D’s close collaborator based in Madrid, Spain.

They will present their current project focused on skin tissue engineering which aims to set up a facility to produce human skin for clinical applications. The skin model is being developed using Regemat’s bioprinter and Biogelx™-INK-GFOGER; our collagen-derived bioink.

If this sounds of interest, and you would like to know more about the webinar in advance, you can read more details here. And if you’re curious, the benefits of our peptide Biogelx-INK platform can be found here.

Jose Manuel and Mario will be answering questions after the webinar, together with our other speaker Dr. Chris Allan, so be sure to register for the webinar here and join us on Tuesday, 21st of January. We would love to have you there!


As you might already know, we are hosting a webinar on the use of 3D bioprinting to generate reproducible skin models. It will be on Tuesday, 21 Jan 2020 and you are invited to register for free here.

During this webinar we will hear about the potential of printing cell-laden biomaterials to create functional skin in vitro. We will learn from experts at Regemat3D who are working on developing their own 3D printed layered skin model. As part of Biogelx’s ongoing collaboration with Regemat3D, researchers from the bioprinting company are using Biogelx-INKs for the generation of such advanced models with the support from our bioink expert Dr. Chris Allan.

Now, we are happy to introduce Chris as the first speaker of the webinar. Chris Allan is a Biomaterial Development Scientist who has worked extensively on the development of our novel range of bioinks, which are based on Biogelx’s proprietary peptide hydrogel technology. On the upcoming webinar he will talk about the requirements of a biomaterial to be suitable for demanding bioprinting applications, and he will introduce Biogelx-INK versatile bioink technology.

Biogelx-INKs are synthetically made but biologically active. The Biogelx material utilized for this specific Regemat3D project is Biogelx™-INK-GFOGER which contains a key six-amino-acid biomimetic sequence that is relevant for the extracellular matrix protein collagen, and which offers the advantage of creating an accurate and standardised scaffold for this particular skin model.

If you’re interested and would like to know more ahead of the webinar next month, you can read about the benefits of our peptide Biogelx-INK platform here, and detail on the specific bioink utilised in the model which will be presented can be found here: Biogelx™-INK-GFOGER.

Chris will be answering questions after the webinar, so be sure to register here and join us on Tuesday, 21st of January, we would love to see you there!

Webinar Spotlight Interview with Sandy Bulloch The Future Is Here: Making In Vitro More In Vivo with Biogelx™ 3D Scaffolds

Sandy Bulloch, Director of Strategic Collaborations

Sandy is a qualified pharmacist who has 30 years of commercial experience in the pharmaceutical and biotechnology industries. He has led multinational market access projects in the fields of drug development and regenerative medicine. He joined Biogelx’s business development team a year and a half ago to support the company’s growth strategy and establish new collaborations with future commercial potential.

 What is Biogelx for those who may not have heard of the company’s novel 3D peptide-based hydrogels scaffolds?

Biogelx was formed as a spin-out company Professor Rein Ulijn’s lab at the University of Strathclyde. Biogelx™ self-assembling synthetic peptide products have rapidly gained a global reputation in the area of 3D cell culture for both Regenerative Medicines and Drug Discovery. The materials’ unique ability to emulate specific physical properties of a wide range of different tissue types offer new opportunities for the development of tailored 3D models for biomedical and pharmaceutical applications. Building on the success of Biogelx™ core technology, the company designed and developed a novel bioink product family (Biogelx™-INKs) which opens the opportunity for the development of advanced three-dimensional tissue models. These hydrogel-based inks are biocompatible and easily printable, exhibiting excellent shear-thinning properties, which reduce the stress experienced by cells when subjected to the printing process. However, the key differentiator of these bioinks is the unique mix of their properties, which ensure versatility and consistency for bioprinting applications.

 What is new for this year as opposed to the previous one at Biogelx?

This year has been hectic for us. We launched the bioink product range early April. We signed off a few strategic collaborations with bioprinter manufacturers, such as 3D Bioprinting Solutions in Brazil, ONSBio in the US and Regemat 3D in Spain. We have also welcomed a distribution agreement with Merck Sigma-Aldrich and start working on the bioink product launch campaign in early January. In the webinar we will present a case study where working along with Regemat 3D and PITI3D, and demonstrate feasibility to develop a skin tissue construct model and we are hopeful of future funding to develop the concept further to tackle the debilitating condition caused by diabetic ulceration.

You mentioned that Biogelx will host a live webinar on January 21. What do the audience gain from attending this webinar?

 We will discuss the potential of 3D printing of biomaterials and cells and maturing them in a bioreactor to create functional skin in the lab. We will talk about the requirements of biomaterials and introduce a versatile bioink technology. Furthermore, we will present a case study on a recently developed 3D printed in vitro skin model.

We will have three great speakers: Dr José Manuel Baena, Founder and CEO, Regemat 3D; Dr Chris Allan, Development Scientist, Biogelx; and Mario Juárez Rodríguez, MSc – Research associate at the Platform for Tissue Engineering and 3D Printing, La Paz University Hospital, Madrid. They will be answering questions after the webinar, so it is worth to register and join us on Tuesday, January 21.

How can people learn more about Biogelx’s peptide-based hydrogel products?

We have an up-to-date website where we regularly publish the latest insight and perspectives from the world of 3D bioprinting along with the newest evidence for our products.  But above all, working in partnership is a priority for Biogelx so you can always contact us in person by emailing me at We are always here to answer questions, help solve problems and develop bespoke solutions.



Spotlight Interview with Robert Topping, Scientist at CordenPharma

A Conversation with Robert Topping, distinguished Scientist at CordenPharma


Robert is currently a Distinguished Scientist at CordenPharma Colorado, continuing development and implementation of manufacturing processes for peptide and highly potent APIs.



  1. What do you hope the audience will learn from this webinar?

I hope the audience will take note of the need to identify, consider & understand the process changes that are often needed in order to control the manufacturing process so that it can deliver the same quality outcomes that are expected based on the smaller scale, discovery and development process knowledge.

  1. What discussions do you look forward to having with the audience?

I would like to hear feedback from the audience on issues they might have experienced and resolved. I think this webinar is an effective medium for sharing practical experience, technical knowledge and gaining insight into problems that others may not have encountered or resolved yet. Large scale peptide manufacturing can present a minefield of problems, but a gold mine of solutions.

  1. What do you enjoy most about your role?

I enjoy the challenge of figuring out what a molecule is doing, what influences the molecule receives, and then creating ways of controlling what that molecule does.

  1. How did you get into the industry?

After graduate school in chemistry, I felt the pharmaceutical industry, and its impact on global health care, was the most value-added career for me as a chemist. I was hired by Syntex in 1987 as part of a team to devise and develop a new, world-leading synthesis and manufacturing process what would soon become Aleve®.  That success nurtured a passion for seeing the whole process, from bench to commercializaton, and for insight into the value of critical medicines in the pharmaceutical industry.

  1. Where is your favourite place in the world and why?

The Olympic Peninsula in Washington state. It is a great place to experience a wide range of nature without being lost in it.

Join Robert on a webinar entitled ‘Scale-up Considerations for Large-Scale Peptide Manufacturing‘ by CordenPharma on 20th November at 8 MST / 10 EST / 16:00 CET.

CordenPharma – Peptide Webinar Blog


CordenPharma’s live webinar on Wed November 20th, titled “Scale-up Considerations for Large-Scale Peptide Manufacturing,” will present concepts that bear differences in the outcomes of peptide synthesis that are dependent on scale. The topics discussed can significantly impact quality and processability, and are often unexpected if scale-up planning only applies mathematical scaling of a small-scale lab synthesis.

The development & implementation in CordenPharma Colorado 15 years ago of the large synthetic process for Fuzeon promoted our strategy for large scale manufacturing and, by establishing bulk raw material networks, lowered costs for building blocks such as Fmoc-amino acids and functionalized resins, while also promoting academic and industrial endeavors for the advancement of synthetic strategies and further evolution of coupling reagents with targeted purposes. Today, all of these factors contribute to making peptide therapeutics more affordable and achievable. The commercial success of large scale peptide manufacturing by a synthetic route extended the horizon that scientists and the pharma industry would look to for developing such products.

The scientific beauty and challenge of peptide synthesis, and specifically the practical, safe & economical manufacturing of peptides, is that each peptide product brings its own unique fingerprint of chemical and physical properties that make it a unique chemical “species”.

The cursory evaluation of peptide synthesis as mere arrangement of a basis set of 20 natural amino acids, implying simplicity of the synthesis, fails to note the dramatic differences that the exponentially large number of permutations of those fundamental building blocks can generate, not to mention the “non-natural” permutations that medicinal discovery & development apply to peptide products for enhanced potency and activity.

As with all things in science, the evolution of the approaches & tools that can be applied to probe and achieve an ever-widening range and diversity of peptide products not only continues, but requires constant modification to transfer peptide discoveries into peptide production. Although many peptides have high levels of specificity & potency, patient populations for these therapeutics continue to dictate the need for large scale manufacturing.

Do you wonder what “peptide” therapeutics will look like in the next 10, 20 or 50 years?  Looking back in time at the size of peptides, the approach to their production and the relative molecular simplicity, compared to now, only our imagination limits us. The evolution continues.

Join Robert on a webinar entitled ‘Scale-up Considerations for Large-Scale Peptide Manufacturing‘ by CordenPharma on 20th November at 8 MST / 10 EST / 16:00 CET.

Navigating Injectable Combination Device & Drug Product Regulations







I am Fabio Stevanon, Director of the Global Injectables Platform at CordenPharma International, a Contract Development & Manufacturing Organization (CDMO) which supplies Active Pharmaceutical Ingredients (APIs), Drug Products & Packaging for the pharma / biotech industry.

I am looking forward to our upcoming webinarNavigating Injectable Combination Device & Drug Product Regulations taking place on Sept 12thbecause it will give attendees a unique opportunity to hear from two speakers: Mark Chipperfield, Principal Consultant & Company Director of Corvus Ltd (one of the most skilled consultants in this industry) and myself, giving an overview of CordenPharma’s injectable capabilities & future strategy as a full-service CDMO.

We are very excited to take you on a journey through Injectable “Combination Products,” which were born out of the exploration on the part pharma companies to integrate medical devices with drug products in an effort to seek more convenient, user-focused drug delivery solutions. These quickly emerging solutions have caused regulations, guidelines and applicable standards to evolve rapidly, leaving many aspects of drug development and lifecycle management unsure how to proceed.

We hope you will learn what IS & what IS NOT a combination device-drug product, gain insight into the major regulation landscape for combined drug & device products (including some technical challenges for injectable Pre-Filled Syringes (PFS) & Auto-injectors), get an overview of how a sound injectable drug product strategy by a CDMO helps navigate industry changes to support drug development goals, and learn ways of partnering with a global CDMO to efficiently commercialize an injectable drug (with specific recommendations on finding solutions for injectable combination device-drug product challenges).

Because this is such a hot topic right now, there has already been a lot of interest in the webinar. Being as this is a journey, we would like to also gain an understanding of the challenges that arise in developing injectable combination products, which could affect various roles within the Injectable field of Device / Combination Product Development including Managers, Supervisors, Senior Staff, Clinical Supply, R&D Managers, Tech Transfer Managers & External Quality, just to name a few.

We also want to learn what you are looking for from a global CDMO in connection with this topic. Your feedback will be extremely useful for us to fine-tune our future strategy to expand our Injectable Drug Product portfolio with a sound mix of technologies (as of now strictly aseptic Fill & Finish, lyophilization, terminal sterilization), balanced a good variety of finished dosage forms (e.g. suspension in near future) and product / container ranges (ampoules, all vial ranges, PFS & cartridges).



A conversation with Gary Hutchinson, Founder and President Modality Solutions and Daniel J. LittlefieldFounder and VP Engineering

 As a founder and the President of Modality Solutions, Gary Hutchinson has developed logistics processes and managed supply chain professional organizations in a variety of industries.


 Daniel Littlefield is a founder of Modality Solutions. He has helped establish Modality Solutions as an innovator in the cold chain logistics industry. Dan recently headed up Modality Solutions’ CDC-sponsored Ebola clinical trial operations project in Sierra Leone and NIH-sponsored clinical trial operations project in Liberia in 2015 and 2016.

  1. What do you hope attendees will gain at your event’s?

Gary: I hope attendees get a deep understanding on how to meet the changing regulatory expectations for monoclonal antibodies and most recently for the new class of immunotherapies. Expectations on drug product testing, the role of simulation and the changing requirements on the role of ASTM testing is all critical to new therapy approval.

Dan: I feel like we’ve really raised the bar on technical rationale for why and how we do simulation testing, and I’m excited to share our thoughts on how it all fits together. We want to share how our validation methodology flows logically from risk assessment through qualification results, and how the logic can be applied to the full spectrum of new treatments.

2. What discussions do you look forward to having with the attendees?

Gary: We love getting and sharing feedback received from regulators around the globe on cold chain validation strategies and expectations on execution. It’s great to see more and more harmonization on a global approach to cold chain validation focused on the patient. We are uniquely positioned to share information because of our involvement in cold chain validation for more than 75 therapies in the last 18 months, but we always love to learn about your experience, too!

Dan:  We work with a lot of very smart people in the industry who are developing new therapies, and a webinar like this helps us to broaden our knowledge base regarding the latest nuances in therapies.  Industry innovation is increasing, and we need to stay sharp about what’s out there, and what’s on the way, so we can ensure the robustness of all the work we do.

3. What do you enjoy most about your role?

Gary: Without a doubt, we love helping our clients navigate an increasing complex cold chain for the latest therapies. We enjoy being involved early in clinical trials to simulate the transport environment on early stage therapies and being part of great teams all the way through approval.

Dan:  We have a great team of engineers, and we’re always working to ensure client success.  We’re always excited when we hear of a successful submission or clinical trial, because we know we’ve done our part to make sure our clients’ patients are getting great new therapies.  Also, because I am an engineer, I personally enjoy the more technical aspects of our work.

4. How did you get into the industry?

Gary: My career in supply chain and logistics started more than 25 years ago after graduating from The Ohio State University in Columbus, Ohio with a master’s degree in business logistics and finance. I entered the life sciences industry in 2000 as part of the great medical device manufacturing team at Edwards Lifesciences.

Dan:  I’ve been an engineer for more than 30 years.  I’ve had a colorful career with a lot of great experiences.  I was fortunate to get my master’s degree in chemical engineering, which has given me more depth in my technical skills.  In addition, my 18 years with DuPont were great to broaden my skillset and address the more practical aspects of statistical and mathematical modeling, heat transfer, and thermodynamics.  As a founder of Modality Solutions, I’ve worked with almost every client, giving me a solid base in the biopharmaceutical industry.

5. Where is your favorite place in the world and why?

Gary: My favorite place in the world is blue water sailing anywhere in the world. I do not get out on the water as much before, but I take any chance I get to recharge out on the ocean.

Dan: My father and I have gone fly fishing together for more than 40 years.  The one vacation I manage to get is to travel to the Bighorn Mountains or Snowy Range in Wyoming.  Of course, I go in July and August, so there isn’t (much) snow, but the scenery is beautiful, and the fishing is pretty good too!


A conversation with Jacob Jewison, Electrical Engineer at Nidec-Kato Engineering

Jacob graduated from Minnesota State University, Mankato with a bachelor’s degree in Electrical Engineering, and has 6 years of experience with Nidec-Kato Engineering working as an Electrical Engineer.

1. What do you hope the audience will learn from this webinar?

I hope the audience will gain a better understanding of what certain machine characteristics are as well as what factors drive them.

2. What discussions do you look forward to having with the audience?

I look forward to discussing reactance requirements and motor starting.

3. What do you enjoy most about your role?

I most enjoy when a customer comes to us with a requirement that hasn’t been solved before, and I get to develop a new design that will fulfil the requirement.

4. How did you get into the industry?

I’ve had an interest in electricity since the 4th grade when in science class we made simple circuits using batteries, switches, light bulbs and motors. This interest led me to pursue a career as an electrician after high school.  Wanting to learn more about electricity, after a couple years I decided to go to college for electrical engineering.  After my first year of college it was my experience as an electrician that landed me an internship here at Kato in the insulation lab building and testing sample coils.

5. Where is your favourite place in the world and why?

My favourite place in the world is out on the hiking trails near Lake Superior in Northern Minnesota, because it’s great to get away from the technology from time to time.

Join Jacob Jewison on the webinar entitled ‘Generator Jargon‘ Nidec – Kato Engineering & Leroy-Somer on 16 July at 3PM London/10AM New York.